X

Trial Profile

A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 28 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tegoprubart (Primary)
Indications IgA nephropathy
Focus Adverse reactions; Therapeutic Use
Sponsors Eledon Pharmaceuticals

Most Recent Events

25 Mar 2024 Status changed from recruiting to discontinued.
20 Sep 2023 This trial has been Discontinued in Poland, according to European Clinical Trials Database record.
21 Jun 2023 This trial has been Discontinued in Spain, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com